Impact of metabolic syndrome on quality of life of liver transplant recipients

Zhenshun Wang, Ning Li* and Dongdong Lin*

Abstract

Objective: The incidence of metabolic syndrome (MS) increases after liver transplantation. This study was performed to evaluate the impact of MS on patients’ quality of life after liver transplantation.

Methods: We collected the medical records of 152 patients during their post-liver transplantation outpatient follow-up. Quality of life was assessed using the Medical Outcomes Study 36-Item Short Form Health Survey. Data on the patients’ general condition as well as MS-related indicators were assessed in all patients. Based on the MS diagnostic criteria proposed by the International Diabetes Federation in 2005, the patients were divided into two groups: those with and without MS. We then analyzed the factors influencing MS and their impact on the patients’ quality of life.

Results: After liver transplantation, age and underlying liver disease were significantly associated with MS and diabetes, and sex and body mass index were associated with central obesity. Central obesity affected the patients’ general health (GH) score and health transition (HT) score, and hypertension affected their GH score and physical component score (PCS).

Conclusions: After liver transplantation, central obesity had a negative impact on patients’ GH score and HT score, and hypertension affected their GH score and PCS.

Keywords
Liver transplantation, metabolic syndrome, quality of life, central obesity, hypertension, 36-Item Short Form

Date received: 7 March 2018; accepted: 8 May 2018

Introduction

Liver transplantation is an effective treatment for patients with end-stage liver disease.1,2 As a result of advances in surgical
techniques and the use of new immunosuppressants, the survival time of patients who have undergone liver transplantation has increased; however, numerous post-transplantation complications still threaten the health of patients. Metabolic syndrome (MS) is a common complication of liver transplantation. The established association between MS and cardiovascular disease reflects an important problem for patients undergoing liver transplantation. Many studies have been performed to assess post-liver transplantation MS worldwide, but the impact of MS on the quality of life (QOL) of liver transplant recipients remains unclear.

In this study, the information of liver transplant recipients was collected and used to retrospectively investigate the incidence of MS and relevant influencing factors. The findings of this study will provide a scientific basis for the diagnosis and treatment of MS and improvement of the QOL of these patients.

**Patients and methods**

**Study design**

The data for this epidemiological cohort study were obtained through structured interviews. The study protocol was approved by the Ethics Committee of Beijing You An Hospital. The methods were performed in accordance with the guidelines approved by the Ethics Committee of Beijing You An Hospital.

**Patients**

Patients who underwent liver transplantation from January 2000 to January 2015 and participated in regular medical follow-up at the Liver Transplantation Center in Beijing You An Hospital were enrolled in this study at least 6 months after the surgical procedure. All patients participating in the study provided written informed consent. Orthotopic liver transplantation was performed in all patients, followed by a standard immunosuppression regimen consisting of tacrolimus or cyclosporine, mycophenolate mofetil (MMF), and steroids. All patients received identical intraoperative and postoperative care. The exclusion criteria were double transplantation and multiple organ transplantation. Weight and height were measured in all patients.

**Questionnaire**

QOL was assessed using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). We collected information regarding the general conditions of patients as well as MS-related indicators. The SF-36 is currently the most widely used questionnaire to assess the QOL of patients after liver transplantation. It contains 36 descriptive items and assesses health in 8 domains associated with physical health [physical functioning (PF), role limitations due to physical problems (RP), bodily pain (BP) and general health (GH)] and mental health [vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH)]. The eight scales are summarized by two component summary scores: the physical component score (PCS) and the mental component score. The scores range from 0 to 100 points; a higher score corresponds to a better domain result. This standard questionnaire does not address sociological information; therefore, the respondents’ age, sex, address, education level, marital status, and economic situation were obtained through other means.

The following MS diagnostic criteria were proposed by the International Diabetes Federation in 2005: body mass index (BMI) of \(>30 \text{ kg/m}^2\), but the waist circumference does not need to be measured; triglyceride level of \(>150 \text{ mg/dL}\);
reduced high-density lipoprotein cholesterol level of <40 mg/dL for males and <50 mg/dL for females; a high fasting glucose level (≥100 mg/dL); and elevated blood pressure (≥130/85 mmHg or relevant antihypertensive treatment). According to the established definition, MS is diagnosed when patients have central (abdominal) obesity, which is a prerequisite, plus any two of the above criteria.

The diagnostic criteria for central obesity are based on the waist circumference. According to the International Diabetes Federation, the reference value for waist circumference among Chinese people is >90 cm for males and >80 cm for females. Extensive controversy has surrounded the waist circumference cut-off point for central obesity in recent years. Previous studies have shown that to predict cardiovascular risk, a BMI of ≥25.0 kg/m² is more sensitive than a waist–hip ratio of >0.90 (males) and >0.85 (females) as an indicator of overweight/obesity in patients with MS. 8

In this study, we used the 1999 World Health Organization diagnostic criteria for diabetes (recommended by the 2003 Barcelona International Consensus), which are as follows: diabetic symptoms and random plasma glucose level of ≥11.1 mmol/L (200 mg/dL), fasting plasma glucose level of ≥7.0 mmol/L (126 mg/dL), or a 2-hour oral glucose tolerance test plasma glucose level of ≥11.1 mmol/L; these values must be measured more than twice.

The diagnostic criteria for hypertension are a systolic blood pressure of ≥140 mmHg and diastolic blood pressure of <90 mmHg, systolic blood pressure of <140 mmHg and diastolic blood pressure of ≥90 mmHg, systolic/diastolic blood pressure of ≥140/90 mmHg, or treatment with antihypertensive drugs after one of the above-mentioned blood pressures was measured prior to medication use.

**Statistical analysis**

Continuous variables are presented as mean ± standard deviation. Qualitative variables are presented as percentage and frequency. Statistical analyses were performed using IBM SPSS Statistics, version 19.0 (IBM Corp., Armonk, NY, USA).

Univariate analysis was conducted to evaluate possible associations between patients with and without MS with respect to demographic and clinical characteristics. The independent t-test, chi-square test, and Fisher’s exact test were used for data comparisons. Multiple logistic regression analysis was used to determine the independent factors that influence MS and its components. The factors that affected QOL were entered into a multivariate stepwise regression analysis. A P value of <0.05 was considered statistically significant.

**Results**

**Patient sociodemographic characteristics and underlying indications for liver transplantation**

In total, 152 patients (125 men, 22 women) were included in this study. The questionnaire response rate was 96.7% (147/152). The patients’ sociodemographic characteristics and liver disease data are shown in Table 1. The average age of the patients was 53.96 ± 9.79 years. The mean follow-up time was 52.91 ± 39.29 months. The percentage of patients who were married was 97.28%.

The patients’ underlying diseases before liver transplantation were as follows: hepatocellular carcinoma (n = 49), hepatitis cirrhosis (n = 43), primary biliary cirrhosis (n = 7), alcoholic cirrhosis (n = 13), acute liver failure (n = 26), and others (n = 9), including hepatic myelopathy and viral hepatitis combined with alcoholic cirrhosis. The types of immunosuppressants used were
tacrolimus (FK506) \( (n = 128) \), cyclosporine A \( (n = 14) \), sirolimus \( (n = 33) \), MMF \( (n = 50) \), and hormone therapy (average dosage of prednisolone = 5 mg/d) \( (n = 8) \).

**Incidence of MS in patients after liver transplantation**

The incidence of MS after liver transplantation was high (46.94%). In the subgroup analysis of MS, central obesity exhibited the highest incidence (53.74%) and dyslipidemia exhibited the lowest incidence (38.78%) among MS components (Table 1).

**Comparison of QOL scores between patients with and without MS and its components**

Compared with other domains, patients’ scores were highest in the PF domain and lowest in the health transition (HT) domain. The results of our study showed that MS had no specific impact on patients’ QOL after liver transplantation. Patients with central obesity had higher GH scores than patients without central obesity. The GH score and PCS of patients with hypertension were lower than those of patients without hypertension \( (P < 0.05, \text{ independent t-test}) \) (Figure 1).

**Factors influencing MS**

The results of the multiple logistic regression analysis of MS and its components (Table 2) showed that age and underlying liver disease were significantly associated with MS (age, \( P = 0.001 \); hepatocellular carcinoma, \( P = 0.036 \)) and diabetes (age, \( P = 0.001 \); hepatocellular carcinoma, \( P = 0.008 \); hepatitis cirrhosis, \( P = 0.009 \)). Sex and BMI were

| Table 1. Patients’ demographic and clinical characteristics |
|-------------------------------------------------------------|
| **Characteristics** |
| **Patients (n = 147)** |
| Body mass index, kg/m² | 24.21 ± 0.28 |
| Age, years | 53.96 ± 9.79 |
| Mean postoperative follow-up time, months | 52.91 ± 39.29 |
| Sex | |
| Female | 22 |
| Male | 125 |
| Marriage status | |
| Married | 143 (97.28) |
| Single | 4 (2.72) |
| Tacrolimus | 128 (87.07) |
| Immunosuppressant regimen | |
| Cyclosporine A | 14 (9.52) |
| Sirolimus | 33 (22.45) |
| Mycophenolate mofetil | 50 (34.01) |
| Hormone | 8 (5.44) |
| Underlying liver disease | |
| Hepatocellular carcinoma | 49 (33.33) |
| Hepatitis cirrhosis | 43 (29.25) |
| Primary biliary cirrhosis | 7 (4.76) |
| Alcoholic cirrhosis | 13 (8.84) |
| Acute liver failure | 26 (17.69) |
| Others | 9 (6.12) |
| Metabolic syndrome and its components | |
| Metabolic syndrome | 69 (46.94) |
| Central obesity | 79 (53.74) |
| Diabetes | 76 (51.70) |
| Hypertension | 72 (48.97) |
| Dyslipidemia | 57 (38.78) |

Data are presented as n, n (%) or mean ± standard deviation.
Figure 1. (a) Comparison of quality of life (QOL) scores (8 domains) between patients with and without metabolic syndrome (MS). (b) Comparison of QOL scores (8 domains) between patients with and without central obesity. (c) Comparison of QOL scores (8 domains) between patients with and without hypertension. PF, physical functioning; BP, bodily pain; RP, role limitations due to physical problems; GH, general health; SF, social functioning; VT, vitality; RE, role limitations due to emotional problems; MH, mental health; PCS, physical component score; MCS, mental component score; HT, health transition.
| Factor                                      | Patients (n = 147) | Multiple logistic regression analysis<sup>a</sup> |
|--------------------------------------------|--------------------|-----------------------------------------------|
|                                            | With MS (n = 69)   | Without MS (n = 78)  | P     | MS   | Central obesity | Dyslipidemia | Hypertension | Diabetes |
|                                            |                    |                   |       |      |                |              |             |         |
|                                            |                    |                   | 0.001<sup>a</sup> | 1.077<sup>**</sup> | – | – | – | 1.068<sup>**</sup> |
|                                            |                    |                   |       |      |                |              |             |         |
|                                            |                    |                   | -    | -    | -   | - | - | - |
|                                            |                    |                   | 0.001<sup>c</sup> | - | 0.246<sup>a</sup> | – | – | – | 0.35 |
|                                            |                    |                   | 0.024<sup>a</sup> | - | 2.057<sup>**</sup> | – | – | – | 3.494<sup>**</sup> |
|                                            |                    |                   | -    | -    | -   | - | - | - |
|                                            |                    |                   | 0.08<sup>c</sup> | - | - | – | – | 3.445<sup>**</sup> |
|                                            |                    |                   | -    | -    | -   | - | - | - |
|                                            |                    |                   | 0.121<sup>d</sup> | 8.399 | – | – | – | 7.116 |
|                                            |                    |                   | (0.950–74.275) |  |   |   |   | (0.982–51.572) |
|                                            |                    |                   |       | 0.953<sup>c</sup> | – | – | – | – |
|                                            |                    |                   |       | 0.93<sup>c</sup> | – | – | – | – |
|                                            |                    |                   |       | 0.198<sup>c</sup> | – | – | – | – |
|                                            |                    |                   |       | 0.371<sup>d</sup> | – | – | – | – |
|                                            |                    |                   |       | 0.151<sup>c</sup> | – | – | – | – |
|                                            |                    |                   |       | 0.376<sup>c</sup> | – | – | – | – |
|                                            |                    |                   |       | 0.167<sup>c</sup> | – | – | – | – |
|                                            |                    |                   |       | 0.608<sup>c</sup> | – | – | – | – |
|                                            |                    |                   |       | 0.57<sup>c</sup> | – | – | – | 0.200 |
|                                            |                    |                   |       |       |       |       |       | (0.037–1.082) |

Data are presented as n, mean ± standard deviation, or odds ratio (95% confidence interval) unless otherwise indicated.

Methods: <sup>a</sup>backward stepwise (Wald), <sup>b</sup>independent t test, <sup>c</sup>chi-square test, <sup>d</sup>Fisher's exact test.

<sup>*</sup>P < 0.05, <sup>**</sup>P < 0.01

MS, metabolic syndrome
associated with central obesity (sex, \(P = 0.038\); BMI, \(P = 0.001\)). However, immunosuppressant agents did not affect MS or its components in our study.

**Impact of MS on patients’ QOL after liver transplantation**

The results of our analysis (Table 3) showed that MS had no specific impact on patients’ QOL after liver transplantation. However, central obesity affected the GH score and HT score, and hypertension affected the GH score and PCS. Diabetes and dyslipidemia had no significant impact on any aspect of QOL. Age was significantly associated with the PF score (\(P < 0.01\)), VT score (\(P = 0.025\)), PCS (\(P = 0.025\)), and HT score (\(P = 0.036\)), and the postoperative follow-up time was associated with the HT score (\(P = 0.001\)). Immunosuppressants, especially cyclosporine A, affected the BP score (\(P = 0.036\)), GH score (\(P = 0.045\)), and HT score (\(P = 0.003\)) of transplant recipients.

**Discussion**

QOL is an important factor with which to assess the value of liver transplantation. QOL is a multifaceted construct that includes both physical and mental domains. Previous studies have proven a significant improvement in QOL (both mental and physical components) after transplantation.\(^9\)

More than 80% of studies have shown improvements in physical functioning, and 60% of studies have shown improvements in mental and social functioning.\(^10\) In the present study, patients’ scores were highest in the PF domain and lowest in the HT domain. Many factors might affect QOL after liver transplantation, such as age, immunosuppressant use, and postoperative complications (Table 3).

Similar to our study, previous studies have shown that MS is a common complication and has a higher incidence after liver transplantation\(^6,11\) (35.6%–58.0%) than in the general population in both the United States\(^12\) (23.7%) and China\(^13\) (12%–14%). Our study also showed high incidences of the components of MS, including hypertension, central obesity, diabetes, and dyslipidemia, which is consistent with similar findings reported previously.\(^14,15\) The impact of MS on patients’ QOL after liver transplantation is multifaceted: long-term diabetes can lead to vascular lesions, dyslipidemia is a high-risk factor for atherosclerosis, hypertension can lead to a high incidence of cerebral vascular accidents, and central obesity can facilitate the emergence of cardiovascular disease risk factors. These complications not only increase patients’ medical expenses but may also be life-threatening in severe cases. However, very few studies have been performed to assess the impact of MS on long-term survival of patients after liver transplantation.

Few studies have investigated the impact of MS on QOL of liver transplantation recipients. Notably, the present study is the first to analyze the impact of MS on QOL of liver transplantation recipients. This study showed that MS has no significant impact on patients’ QOL. Nevertheless, we found that central obesity affected the GH and HT scores and that hypertension affected the GH score and PCS of transplant recipients, and the differences were statistically significant. These results are theoretically and practically important to adjust immunosuppressive agents when patients develop MS.

Various factors affect the incidence of MS, including many preoperative factors. For example, underlying diseases, obesity, advanced age, and donor gene polymorphisms are risk factors for metabolic diseases after liver transplantation.\(^16\) However, long-term immunosuppressive therapy is a well-known and important cause of MS. In recent years, the results of studies on hormone reduction or removal and minimal calcineurin inhibitor
Table 3. Results of multivariate linear regression analysis of quality of life

| Factor                        | PF       | BP       | RP       | GH       | SF       | VT       | RE       | MH       | PCS      | MCS      | HT       |
|-------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|                               | t        | P        | t        | P        | t        | P        | t        | P        | t        | P        | t        |
| Age                           | -4.200   | 0.000**  | -        | -        | -        | -        | -2.268   | 0.025*   | -        | -        | -2.660   | 0.036**  |
| Postoperative follow-up time  | -        | -        | -        | -        | -        | -        | -        | -        | -        | -        | -        | -3.420   | 0.001**  |
| Cyclosporine A                | -        | -        | 2.115    | 0.036*   | -        | -        | 2.019    | 0.045*   | -        | -        | -        | -        | 3.018    | 0.003**  |
| Central obesity               | -        | -        | -        | -        | -        | -        | 2.801    | 0.006**  | -        | -        | -        | -        | 2.911    | 0.004**  |
| Dyslipidemia                  | -        | -        | -        | -        | -        | -        | -        | -        | -        | -        | -        | -        | -        | -        |
| Hypertension                  | -        | -        | -        | -        | -        | -        | -2.814   | 0.006**  | -        | -        | -        | -        | -2.024   | 0.045*   |

*Stepwise analysis
**P < 0.05, ***P < 0.01
PF, physical functioning; BP, bodily pain; RP, role limitations due to physical problems; GH, general health; SF, social functioning; VT, vitality; RE, role limitations due to emotional problems; MH, mental health; PCS, physical component score; MCS, mental component score; HT, health transition.
Immunosuppressive regimens have shown that hormone-free MMF or a combination of MMF and reduced calcineurin inhibitor treatment can reduce the adverse effects of other immunosuppressants on metabolic diseases while ensuring the efficacy of immunosuppression in patients after liver transplantation. Although the present study showed no direct correlation between any immunosuppressant and MS, hormones are generally considered to be related to MS after liver transplantation. However, hormone therapy was withdrawn during the early postoperative period in our patients. Accordingly, the impact of long-term hormone use on MS requires further study.

Many recent studies have shown that cardiovascular disease is one of the most common late causes of death, accounting for 12% to 16% of deaths (primary or major contributing causes) among liver transplant recipients. Due to the established association between MS and cardiovascular disease, additional attention should be directed toward the management of MS.

In summary, MS is a common complication after liver transplantation and has a significantly higher incidence in post-liver transplant patients than in the general population. Additionally, central obesity exhibits the highest incidence among MS components and shows an upward trend with time. MS has no significant impact on patients’ QOL after liver transplantation. However, central obesity affected the GH and HT scores and hypertension affected the GH scores and PCS of transplant recipients in the present study.

Acknowledgements
The authors would like to thank all included patients for their willingness to participate in this study. We acknowledge the valuable contributions of the doctors and nurses in the General Surgery Department of Beijing You An Hospital China.

Disclosure of conflict of interest
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Beijing Municipal Administration of Hospitals Key Medicine Specialty Development Plan (grant No. ZYLX201311), the Fengtai Health System Science and Technology Programme (grant No. 2013-17), the National Science and Technology Major Project (grant No. 2017ZX10203205-006-003), and the Beijing Municipal Health System High Level Personnel Training Programme (grant No. 2013-3-074).

References
1. Mehrabi A, Fonouni H, Müller SA, et al. Current concepts in transplant surgery: liver transplantation today. *Langenbecks Arch Surg* 2008; 393: 245–260.
2. Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Hepatology* 2014; 59: 1144–1165. DOI: 10.1002/hep.26972.
3. Kallwitz ER. Metabolic syndrome after liver transplantation: Prevalent illness or common consequence? *World J Gastroenterol* 2012; 18: 3627–3634.
4. Laish I, Braun M, Mor E, et al. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. *Liver Transpl* 2011; 17: 15–22.
5. Pérez MJ, García DM, Taybi BJ, et al. Cardiovascular risk factors after liver transplantation: analysis of related factors. *Transplant Proc* 2011; 43: 739–741.
6. Tan HL, Lim KBL, Iyer SG, et al. Metabolic syndrome after a liver transplantation in an Asian population. *HPB* 2015; 17: 713–722.
7. Zimmet P, Magliano D, Matsuzawa Y, et al. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005; 12: 295–300.
8. Huang PL. A comprehensive definition for metabolic syndrome. Disease Models & Mechanisms 2009; 2: 231–237.
9. Belle SH, Porayko MK, Hoofnagle JH, et al. Changes in quality of life after liver transplantation among adults. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database (LTD). Liver Transpl Surg 1997; 3: 93–104.
10. Bravata DM, Olkin I, Barnato AE, et al. Health-related quality of life after liver transplantation: a meta-analysis. Liver Transpl 1999; 5: 318–331.
11. Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109–1114. 2007/08/01. DOI: 10.1002/lt.21126.
12. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745.
13. Further Study Of Risk Factors For Stroke And Coronary Heart Disease group. [The prevalence of metabolic syndrome in a 11 provinces cohort in China]. Zhonghua Yu Fang Yi Xue Za Zhi 2002; 36: 298–300 [in Chinese, English Abstract].
14. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403–414.
15. Kelly DA, Bucuvalas JC, Alonso EM, et al. Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3–26.
16. Parekh J, Corley DA and Feng S. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation. Am J Transplant 2012; 12: 2181–2187.
17. Watt KD. Metabolic syndrome: Is immuno-suppression to blame? Liver Transpl 2011; 17(Suppl 3): S38–S42.
18. Goralczyk AD, Bari N, Abu-Ajaj W, et al. Calcineurin Inhibitor Sparing With Mycophenolate Mofetil in Liver Transplantation: A Systematic Review of Randomized Controlled Trials. Am J Transplant 2012; 12: 2601–2607.
19. Takada Y, Kaido T, Asonuma K, et al. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus–positive recipients of living donor liver transplantation. Liver Transpl 2013; 19: 896–906.
20. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7: 811–815.
21. Tome S, Wells JT, Said A, et al. Quality of life after liver transplantation. A systematic review. J Hepatol 2008; 48: 567–577.
22. Watt KD, Pedersen RA, Kremers WK, et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420–1427.